Von Potter

673 total citations
8 papers, 154 citations indexed

About

Von Potter is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Von Potter has authored 8 papers receiving a total of 154 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Genetics and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Von Potter's work include Cancer Immunotherapy and Biomarkers (4 papers), Glioma Diagnosis and Treatment (3 papers) and Brain Metastases and Treatment (2 papers). Von Potter is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Glioma Diagnosis and Treatment (3 papers) and Brain Metastases and Treatment (2 papers). Von Potter collaborates with scholars based in United States, Italy and Australia. Von Potter's co-authors include Muhammad Wasif Saif, Solmaz Sahebjam, David A. Reardon, Timothy F. Cloughesy, Michael Lim, John H. Sampson, Nicholas Butowski, Antonio Omuro, Joachim M. Baehring and Alexandros-Georgios Chalamandaris and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Von Potter

8 papers receiving 152 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Von Potter United States	5	120	53	37	37	32	8	154
Karolina Benesova Germany	7	178 1.5×	45 0.8×	17 0.5×	49 1.3×	48 1.5×	21	215
Harald Zeuner Switzerland	6	99 0.8×	23 0.4×	62 1.7×	35 0.9×	52 1.6×	11	143
Allison Barraclough Australia	8	87 0.7×	30 0.6×	106 2.9×	21 0.6×	20 0.6×	29	152
Melody Mendenhall United States	6	116 1.0×	13 0.2×	23 0.6×	30 0.8×	49 1.5×	14	200
Michael Devitt United States	6	43 0.4×	63 1.2×	58 1.6×	33 0.9×	19 0.6×	31	148
José Antonio Queizán Spain	7	58 0.5×	48 0.9×	26 0.7×	10 0.3×	18 0.6×	13	169
Mu‐Chen Zhang China	7	109 0.9×	42 0.8×	150 4.1×	20 0.5×	25 0.8×	16	210
Fushen Sha China	4	68 0.6×	44 0.8×	75 2.0×	13 0.4×	12 0.4×	6	113
Gloria Margiotta Casaluci Italy	5	60 0.5×	34 0.6×	72 1.9×	9 0.2×	19 0.6×	11	99
Barbara Mankel Germany	6	72 0.6×	36 0.7×	76 2.1×	10 0.3×	18 0.6×	12	131

Countries citing papers authored by Von Potter

Since Specialization

Citations

This map shows the geographic impact of Von Potter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Von Potter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Von Potter more than expected).

Fields of papers citing papers by Von Potter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Von Potter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Von Potter. The network helps show where Von Potter may publish in the future.

Co-authorship network of co-authors of Von Potter

This figure shows the co-authorship network connecting the top 25 collaborators of Von Potter. A scholar is included among the top collaborators of Von Potter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Von Potter. Von Potter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Omuro, Antonio, David A. Reardon, John H. Sampson, et al.. (2022). Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology Advances. 4(1). vdac025–vdac025. 40 indexed citations

Lal, Ashutosh, R. Clark Brown, Thomas D. Coates, et al.. (2021). Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease. Blood. 138(Supplement 1). 4162–4162. 2 indexed citations

Fakih, Marwan, Kanwal Raghav, David Chang, et al.. (2021). Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).. Journal of Clinical Oncology. 39(15_suppl). 3560–3560. 52 indexed citations

Armstrong, Andrew J., Michael S. Gordon, Melissa A. Reimers, et al.. (2021). Abstract P202: Initial findings from an ongoing first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer. Molecular Cancer Therapeutics. 20(12_Supplement). P202–P202. 8 indexed citations

Weller, Michael, David A. Reardon, Alba A. Brandes, et al.. (2019). ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE. Neuro-Oncology. 21(Supplement_6). vi12–vi12. 1 indexed citations

Lim, Michael, Antonio Omuro, Gordana Vlahovic, et al.. (2017). Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM). Annals of Oncology. 28. v109–v109. 18 indexed citations

Lansigan, Frederick, et al.. (2010). A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma.. Blood. 116(21). 2816–2816. 1 indexed citations

Saif, Muhammad Wasif, et al.. (2008). Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemotherapy and Pharmacology. 63(6). 1017–1022. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact